Skip to main content

Table 1 Recent informative trials and results of T-cell-replete haploidentical stem cell transplantation

From: How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Reference, year, ref, and median age Patients (No.) Diagnosis Graft ANC median (range) PLT median (range) GVHD TRM Relapse LFS OS
Acute II–IV Chronic
Unmanipulated haplo-SCT with ATG
Di Bartolomeo P, et al. [57] (37) 80 HM G-BM 21 (12–38) 28 (14–185) 24 % 17 % at 2 yr 36 % at 3 yr 21 % at 1 yr 38 % at 3 yr 45 % at 3 yr
Wang Y, et al. [10] (25) 1210 HM G-BM + G-PB 13 (8–49) 16 (5–100) 40 % 50 % 17 % at 3 yr 17 % at 3 yr 67 % at 3 yr 70 % at 3 yr
Luo Y, et al. [14] (25) 99 HM G-PB 12 (8–24) 15 (6–53) 42.4 % 41.4 % at 2 yr 30.5 % at 5 yr 14.2 % at 5 yr 58.3 % at 5 yr 60.8 % at 5 yr
Gao L, et al. [66] (25.4) 26 SAA G-PB + G-BM 13 (11–19) 13 (10–21) 8.0 % 40 % 15.4 % at 2 yr NA NA 84.6 % at 2 yr
Peccatori J, et al. [19] (48) 121 HM G-PB 17 (11–61) 19 (7–154) 35 % 47 % at 2 yr 31 % at 3 yr 48 % at 3 yr 20 % at 3 yr 25 % at 3 yr
Shin SH, et al. [29] (48) 60 MDS G-PB 12 (8–23) 15 (6–132) 36.7 % 48.3 % 23.3 % at 2 yr 34.8 % at 2 yr 41.9 % at 2 yr 46.6 % at 2 yr
Yahng SA, et al. [120] (41) 80 AML G-PB 11 10 47.5 % 45 % 12.2 % at 2 yr 26.6 % at 2 yr 61.1 % at 2 yr 66 % at 2 yr
Lin X, et al. [78] (23) 105 HM G-PB 14 (10–25) 16 (9–38) 21.9 % 24.1 % at 2 yr 30.5 % at 3 yr 21.9 % at 3 yr 41.1 % at 3 yr 50.6 % at 3 yr
TCR haplo-SCT with PT/Cy
Raiola AM, et al. [38] (45) 92 HM SS-BM (92) 18 (11–32) 32 (5–83) 14 % 15 % 18 % at 1000 days 35 % 43 % at 4 yr 52 % at 4 yr
McCurdy SR, et al. [36] (55) 372 HM SS-BM 90 %a 88 %b 32 % at 6 m 13 % at 2 yr 11 % at 1 yr 46 % at 3 yr 40 % at 3 yr 50 % at 3 yr
Bacigalupo A, et al. [37] (47) 148 HM SS-BM 17 (13–32) NA 18 % 20 % at 2 yr 14 % at 4 yr 27 % at 4 yr NA 77 % for CR1
49 % for CR2
38 % for AD
Solomon SR, et al. [61] (46) 30 HM G-PB 16 (NA) 25 (NA) 43 % 56 % 3 % at 2 yr 24 % at 2 yr 73 % at 2 yr 78 % at 2 yr
Cieri N, et al. [64] (55) 40 HM G-PB 18 (13–45) 16 (9–100) 15 % 20 % at 1 yr 17 % at 1 yr 35 % at 1 yr 48 % at 1 yr 56 % at 1 yr
Esteves I, et al. [65] (17) 16 SAA SS-BM (13) G-PB (3) 19 (16–29) 21 (20–29) 13 % 20 % 32.9 % at 1 yr NA NA 67.1 % at 1 yr
Ciurea SO, et al. [62] (NA) 104c AML SS-BM (85) G-PB (19) 90 % 88 % 16 % 30 % at 3 yr 14 % at 3 yr 44 % at 3 yr NA 45 % at 3 yr
88d AML SS-BM (77) G-PB (11) 93 % 88 % 19 % 34 % at 3 yr 9 % at 3 yr 58 % at 3 yr NA 46 % at 3 yr
Kasamon YL, et al. [59] (61) 271 HM SS-BM 88–93 % 84–89 % 33 % at 6 m 12 % at 1 yr 10 % at 1 yr 46 % at 3 yr 37 % at 3 yr 46 % at 3 yr
  1. Published between 2013 and 2015
  2. Ref reference, Pts patients, No. number, ANC absolute neutrophil count, PLT platelet, GVHD graft-versus-host disease, TRM transplant-related mortality, LFS leukemia-free survival, OS overall survival, haplo-SCT haploidentical stem cell transplantation, ATG anti-thymocyte globulin, HM hematological malignancies, G-BM granulocyte colony-stimulating factor (G-CSF)-primed bone marrow, yr year, G-PB G-CSF-mobilized peripheral blood stem cell grafts, UCB umbilical cord blood, NA not available, AL acute leukemia, SAA severe aplastic anemia, MDS myelodysplastic syndrome, AML acute myeloid leukemia, PT/Cy posttransplant cyclophosphamide, SS-BM steady-state bone marrow, m months, AD advanced disease
  3. aIndicates the probability of neutrophil recovery by day 30
  4. bIndicates the probability of platelet recovery ≥20,000/μL by day 60
  5. cIndicates that patients received myeloablative conditioning regimens
  6. dIndicates that patients received reduced intensity conditioning regimens